Feb 17 (Reuters) - The European Commission has approved a higher dose of Novo Nordisk's (NOVOb.CO), opens new tab popular weight-loss drug Wegovy, the Danish drugmaker said on Tuesday.
Delayed diagnoses and overstretched services leave many children without timely support. New AI-powered tools are being tested as part of the solution.